The Role of Ankaferd Blood Stopper and Oxytocin as Potential Therapeutic Agents in Endometriosis: A Rat Model

Current Medical Science volume 40, pages556–562(2020)Cite this article

Summary

To evaluate the potential effect of Ankaferd Blood Stopper (ABS) and oxytocin (OT) in an experimental endometriosis model, 18 female Sprague Dawley rats were used in this study. The animals were divided randomly into three groups after surgical induction of endometriosis: group 1: control group (isotonic NaCl, 1 mL/kg/day, intramuscular, n=6); group 2: OT group (OT, 80 U/kg/day, intramuscular, n=6); group 3: ABS group (ABS, 1.5 mL/kg/day, intraperitoneal, n=6). Each group was treated for four weeks (two times per week). Volumes of endometriotic explants were measured in biopsy samples for histopathological analysis. Vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and tumour necrosis factor (TNF-α) levels were measured in plasma and peritoneal fluid. Endometriotic explant volumes were significantly decreased after OT administration (P<0.0001). The epithelial score was significantly decreased in both treatment groups compared to the control group (P<0.05). TUNEL immunohistochemistry showed more apoptotic changes in the endometriosis foci (gland epithelium and surrounding tissue) in the OT group than in the control group (P<0.05). The levels of VEGF, MCP-1, and TNF-α were significantly reduced in the OT group (P<0.05), whereas no significant changes in protein levels were found in the ABS-applied group. The results indicate that OT has greater potential as a therapeutic agent in experimentally induced peritoneal endometriosis, where ABS, which is a VEGF modulator, appears to act through different mechanisms to show its palliative effects on a rat model of peritoneal endometriosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1

    Bulun SE. Endometriosis. N Engl J Med, 2009,360(3): 268–279

    CAS  Article  Google Scholar 

  2. 2

    Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol, 1927, 14:422–469

    Article  Google Scholar 

  3. 3

    Braun DP, Ding J, Dmowski WP. Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-alpha in women with endometriosis. Fertil Steril, 2002, 78(4):727–732

    Article  Google Scholar 

  4. 4

    Jiang QY, Wu RJ. Growth mechanisms of endometriotic cells in implanted places: a review. Gynecol Endocrinol, 2012, 28(7):562–567

    Article  Google Scholar 

  5. 5

    Bourlev V, Volkov N, Pavlovitch S, et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction, 2006, 132(3):501–509

    CAS  Article  Google Scholar 

  6. 6

    Ulukus M, Ulukus EC, Tavmergen Goker EN, et al. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril, 2009, 91(3):687–693

    CAS  Article  Google Scholar 

  7. 7

    Mechsner S, Bartley J, Loddenkemper C, et al. Oxytocin receptor expression in smooth muscle cells of peritoneal endometriotic lesions and ovarian endometriotic cysts. Fertil Steril, 2005, 83:1220–1231

    CAS  Article  Google Scholar 

  8. 8

    Simsek Y, Celik O, Karaer A, et al. Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet, 2012,286(3):777–783

    CAS  Article  Google Scholar 

  9. 9

    Goker H, Haznedaroglu I, Ercetin S, et al. Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper. J Int Med Res, 2008, 36(1):163–170

    CAS  Article  Google Scholar 

  10. 10

    Lee SJ, Umano K, Shibamoto T, et al. Identification of volatile components in basil (Ocimum basilicum L.) and thyme leaves (Thymus vulgaris L.) and their antioxidant properties. Food Chem, 2005, 91(1):131–137

    CAS  Article  Google Scholar 

  11. 11

    Simsek C, Selek S, Koca M, et al. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper. SAGE Open Med, 2017, 5:2050312117722569

    Article  Google Scholar 

  12. 12

    Sheela ML, Ramakrishna MK, Salimath BP. Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by Glycyrrhiza glabra. Int Immunopharmacol, 2006, 6(3):494–498

    CAS  Article  Google Scholar 

  13. 13

    Vernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril, 1985, 44(5):684–694

    CAS  Article  Google Scholar 

  14. 14

    Güney M, Oral B, Karahan N, et al. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril, 2008, 89(4):934–42

    Article  Google Scholar 

  15. 15

    Petersson M, Wiberg U, Lundeberg T, et al. Oxytocin decreases carrageenan induced inflammation in rats. Peptides, 2001, 22(9):1479–1484

    CAS  Article  Google Scholar 

  16. 16

    Cipil HS, Kosar A, Kaya A, et al. In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost, 2009, 15(3):270–276

    Article  Google Scholar 

  17. 17

    Keenan JA, Williams-Boyce PK, Massey PJ, et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril, 1999, 72(1):135–141

    CAS  Article  Google Scholar 

  18. 18

    Giudice LC, Kao LC. Endometriosis. Lancet, 2004,364(9447):1789–1799

    Article  Google Scholar 

  19. 19

    Young VJ, Ahmad SF, Brown JK, et al. Peritoneal VEGF-A expression is regulated by TGF-β1 through an ID1 pathway in women with endometriosis. Sci Rep, 2015, 5:16859

    CAS  Article  Google Scholar 

  20. 20

    Griffith JS, Rodgers AK, Schenken RS. Reviews: in vitro models to study the pathogenesis of endometriosis. Reprod Sci, 2010, 17(1):5–12

    CAS  Article  Google Scholar 

  21. 21

    Jiang L, Yan Y, Liu Z, et al. Inflammation and endometriosis. Front Biosci (Landmark Ed.), 2016,21: 941–948

    CAS  Article  Google Scholar 

  22. 22

    Wei J, Zhao B, Zhang C, et al. Jiawei Foshou San Induces Apoptosis in Ectopic Endometrium Based on Systems Pharmacology, Molecular Docking, and Experimental Evidence. Evid Based Complement Alternat Med, 2019, 2019:2360367

    PubMed  PubMed Central  Google Scholar 

  23. 23

    Dmowski WP, Ding J, Shen J, et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod, 2001,16(9): 1802–1808

    CAS  Article  Google Scholar 

  24. 24

    Celik O, Aydin S, Celik N, et al. Peptides: Basic determinants of reproductive functions. Peptides, 2015, 72:34–43

    CAS  Article  Google Scholar 

  25. 25

    Yuan L, Liu S, Bai X, et al. Oxytocin inhibits lipopolysaccharide-induced inflammation in microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice. J Neuroinflammation, 2016, 13(1):77

    Article  Google Scholar 

  26. 26

    Haznedaroglu BZ, Beyazit Y, Walker SL, et al. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol, 2012, 83(1):21–34

    Article  Google Scholar 

  27. 27

    Hasgul R, Uysal S, Haltas H, et al. Protective effects of Ankaferd blood stopper on aspirin-induced oxidative mucosal damage in a rat model of gastric injury. Toxicol Ind Health, 2014, 30(10):888–895

    Article  Google Scholar 

  28. 28

    Büyük B, Beyazit F. The efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats. Turk J Obstet Gynecol, 2019, 16(1):7–14

    Article  Google Scholar 

  29. 29

    Yeniel AÖ, Erbas O, Ergenoglu AM, et al. Effect of oxytocin treatment on explant size, plasma and peritoneal levels of MCP-1, VEGF, TNF-α and histopathological parameters in a rat endometriosis model. Eur J Obstet Gynecol Reprod Biol, 2014, 175:134–139

    CAS  Article  Google Scholar 

  30. 30

    Salmassi A, Acar-Perk B, Schmutzler AG, et al. Apoptosis resistance in endometriosis. Bioimpacts, 2011, 1(2):129–134

    PubMed  PubMed Central  Google Scholar 

  31. 31

    Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol, 2010, 202(4):346.e 1–8

    Article  Google Scholar 

  32. 32

    Huang M, Li X, Guo P, et al. The abnormal expression of oxytocin receptors in the uterine junctional zone in women with endometriosis. Reprod Biol Endocrinol, 2017, 15(1):1

    Article  Google Scholar 

  33. 33

    Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpresion of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril, 2013, 99(1):231–240

    CAS  Article  Google Scholar 

  34. 34

    Sippel LM, Allington CE, Pietrzak RH, et al. Oxytocin and Stress-related Disorders: Neurobiological Mechanisms and Treatment Opportunities. Chronic Stress (Thousand Oaks), 2017,1

  35. 35

    Garrido-Urbani S, Deblon N, Poher AL, et al. Inhibitory role of oxytocin on TNF-α expression assessed in vitro and in vivo. Diabetes Metab, 2018,44(3):292–295

    CAS  Article  Google Scholar 

  36. 36

    Ahmed MA, Elosaily GM. Role of Oxytocin in deceleration of early atherosclerotic inflammatory processes in adult male rats. Int J Clin Exp Med, 2011, 4(3):169–178

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, School of Medicine, Ege University, Izmir, 35100, Turkey

    Ismet Hortu, Gokay Ozceltik & Murat Ulukus

  2. Department of Stem Cell, Institute of Health Sciences, Ege University, Izmir, 35100, Turkey

    Ismet Hortu

  3. Department of Biochemistry, School of Medicine, Ege University, Izmir, 35100, Turkey

    Elif Karadadas

  4. Department of Physiology, School of Medicine, Istanbul Bilim University, Istanbul, 34394, Turkey

    Oytun Erbas

  5. Department of Histology and Embryology, School of Medicine, Mugla Sitki Kocman University, Mugla, 48000, Turkey

    Gurkan Yigitturk

Authors
  1. Ismet Hortu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gokay Ozceltik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elif Karadadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oytun Erbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gurkan Yigitturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Murat Ulukus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ismet Hortu.

Ethics declarations

The authors declare that they have no competing interests.

Additional information

This study was supported by Ege University School of Medicine-Research Funds, Izmir, Turkey (No. 2011-TIP-090).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hortu, I., Ozceltik, G., Karadadas, E. et al. The Role of Ankaferd Blood Stopper and Oxytocin as Potential Therapeutic Agents in Endometriosis: A Rat Model. CURR MED SCI 40, 556–562 (2020). https://doi.org/10.1007/s11596-020-2213-1

Download citation

Key words

  • endometriosis
  • Ankaferd Blood Stopper
  • oxytocin
  • cytokines